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Mònica Bayés
Centro Nacional de Análisis Genómico (CNAG-CRG)
Evaluadora ERA PerMed 2018, 2019 y 2020
Errores frecuentes:
1- Propuestas NO alineadas con los objetivos de la convocatoria
2- Propuestas NO equilibradas (ambición versus realismo)
3- Propuestas SIN detalles en relación a la metodología o el posible impacto
4- Propuestas que NO desarrollan en profundidad algún aspecto RRI (Investigación e Innovación Responsable)
5- Propuestas que NO tienen en cuenta infraestructuras, plataformas o asociaciones europeas existentes 
6- Propuestas NO estructuradas
1- Propuestas NO alineadas con los objetivos de la convocatoria
Texto de la convocatoria ERAPerMed 2020 
“The overall objectives of the call is to support translational research projects in the field of Personalised Medicine*”
*Definition of Personalised Medicine in the call text: 
“Personalized medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. 
molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right 
time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.”
“Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 
or 2”
Ejemplos de comentarios de los evaluadores:
“…However, the links with clinical applications for personalized medicine are extremely remote.”
“There will be no impact in the clinic at short or medium-term.”
“Research Area 3B is not covered by WP1 which contains no specific tasks regarding research on legal, 
ethical, social or security aspects.”
“At its current form, the proposal is not tackling Research Area 3A as it shows no plans for optimizing or
implementing the advances in the in health care system.”
“No expertise in Area 3, which will hamper the translation of the new assay into the health care systems.”
1- Propuestas NO alineadas con los objetivos de la convocatoria
Excelencia Impacto Implementación
2- Propuestas NO equilibradas (ambición versus realismo)
- Excelencia: contribución significativa a un avance del conocimiento.
- Propuestas poco novedosa versus propuestas poco realistas
2- Propuestas NO equilibradas (ambición versus realismo)
Ejemplos de comentarios de los evaluadores:
“The novelty is therefore reduced (tools already exist and it is not clear how they will be improved)”
“ What is that XXX achieves further to already existing projects? 
“WP1 will examine only peripheral biomarker candidates already described in the literature”
“Is it really realistic to believe that such a diagnostic method could be used in routine in the clinic?”
·I am not sure if it is possible within the limited time frame of the proposal to create this model,….”
3- Propuestas SIN detalles en relación a la metodología o el posible impacto
Excelencia Impacto Implementación
- Propuestas en las que no se proporciona suficiente detalle sobre la metodología (número de muestras, 
procedencia y criterios de selección de las muestras, métodos experimentales, análisis de los datos 
obtenidos, etc)
- Propuestas en las que no se proporciona suficiente detalle sobre el impacto (cuantificación de los 
beneficios, usuarios finales, plan para la explotación de los resultados, etc). 
Ejemplos de comentarios de los evaluadores:
“It is unfortunate that the 100 samples selection was not more clearly described…”
“The applicants state that FFPE samples will be used to analyze …. How? This section lacks clarity.”
“A better description of the bioinformatics and the insights gained would have been appreciated.”
“How the outcomes of the research will impact at clinical/healthcare level is however not sufficiently 
discussed”
“The proposal does not explain the plan for exploiting the results”
3- Propuestas SIN detalles en relación a la metodología o el posible impacto
4- Propuestas que NO tratan en profundidad aspectos RRI (Investigación e Innovación 
Responsable)
ASPECTOS RRI Propuesta 2020 ERAPerMed
ÉTICA 3.13. ETHICAL ISSUES OF THE PROJECT PROPOSAL
GÉNERO 3.12. INCLUSION OF GENDER AND/OR SEX ANALYSIS
GOBERNANZA 3.4. WORK PLAN (includes project coordination and management)
ACCESO ABIERTO 3.14. DATA MANAGEMENT STRATEGY/PLAN
PARTICIPACIÓN CIUDADANA 3.11. PATIENT INVOLVEMENT
EDUCACIÓN CIENTÍFICA
4- Propuestas que NO tratan en profundidad aspectos RRI (Investigación e 
Innovación Responsable)
Ejemplos de comentarios de los evaluadores:
“They unfortunately do not address in detail dissemination of results and exploitation of the potential 
proposal outcome”
“Missing informed consent procedures, details on incidental findings policy....”
“However, It is unclear what will be the female:male ration in the patient cohort.”
“The management structure was not described in sufficient detail to be effective.”
“One patient organisation has been contacted, but there is no LoI.”
“Procedures for data sharing and secure repositories are not described in the proposal.”
5- Propuestas que NO tienen en cuenta infraestructuras, plataformas o asociaciones 
europeas existentes 
Texto de la convocatoria/ guía ERAPerMed 2020
ERA PerMed is closely linked to the International Consortium for Personalised Medicine (ICPerMed4), established in 
November 2016. The Action Plan5 of ICPerMed builds on the Strategic Research and Innovation Agenda (SRIA) 
“Shaping Europe's Vision for Personalised Medicine”6 developed by PerMed in 2015.
Please, take note of European Research Infrastructures/platforms that could be helpful: 
- Biobanking and Biomolecular Resources Research Infrastructure (BBMRI): http://bbmri-eric.eu/about 
- The European Life Sciences Infrastructure for Biological Information (ELIXIR): https://www.elixir-
europe.org/personalised-medicine 
- European infrastructure for translational medicine (EATRIS); http://eatris.eu/ 
- European Clinical Research Infrastructure Network (ECRIN); http://www.ecrin.org/ 
- European High Capacity Screening Network(EU-Openscreen); http://www.eu-openscreen.eu/ 
- European Infrastructure for Phenotyping, Archiving and Distribution of Mouse Models (INFRAFRONTIER): 
https://www.infrafrontier.eu/
5- Propuestas que NO tienen en cuenta infraestructuras, plataformas o asociaciones 
europeas existentes 
Ejemplos de comentarios de los evaluadores:
“An international patient umbrella organisation would be helpful in the part on the patient 
representatives involvement as it would facilitate the spread and inclusion of other countries not 
represented by the project.“
“Compatibility with GA4GH standards and ELIXIR Interoperability platform is unclear”
“Coordination of the multicentric clinical trial should be done through ECRIN”
6- Propuestas NO estructuradas
- Orden de los WPs y tareas sin una lógica, con títulos no explicativos
- Ausencia de figuras o gráficos explicativos
- Nomenclatura no coherente
Ejemplos de comentarios de los evaluadores:
“Organization and names of the WPs and tasks are a bit confusing.”
“The description of the rationale for the proposal is confused and makes poor reference to the state of the art of 
the field outside the consortium. In addition, the proposal switches back and forward from….”
“The proposal suffers from a lack of clarity, which makes it hard to read / confusing.”
“In general, the proposal has too many WPs (9 WPs for a 3 year project) and description of WPs 1, 2 and 3 is 
poor.”
“It would have been nice to have a diagram in the proposal with the workflow and interactions.”
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GRACIAS!
